Table 1.
Age-standardized hepatocellular carcinoma and biliary tract cancer-related mortality rate and APC among US adults ≥25 years in 2018–2023
| No. deaths (age-standardized mortality rate per 100,000 persons) |
Average APC (95% CI) |
||||||
|---|---|---|---|---|---|---|---|
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2018–2023 | |
| Underlying cause of death | |||||||
| Hepatocellular carcinoma | 20,122 (7.95) | 20,017 (7.72) | 20,142 (7.60) | 20,038 (7.59) | 20,216 (7.38) | 20,395 (7.42) | –1.4 (–2.0, –0.7)* |
| Intrahepatic cholangiocarcinoma | 7,459 (2.97) | 7,807 (3.04) | 7,955 (3.04) | 8,554 (3.31) | 8,609 (3.22) | 9,370 (3.49) | 3.1 (1.2, 4.9)* |
| Extrahepatic cholangiocarcinoma | 925 (0.37) | 966 (0.37) | 988 (0.37) | 1,037 (0.40) | 1,033 (0.38) | 1,004 (0.37) | 0.4 (–1.5, 2.4) |
| Gallbladder cancer | 2,174 (0.86) | 2,130 (0.82) | 2,258 (0.86) | 2,118 (0.82) | 2,077 (0.77) | 2,158 (0.79) | –1.9 (–3.8, –0.0)* |
| Ampullar of Vater cancer | 267 (0.11) | 266 (0.10) | 294 (0.11) | 286 (0.11) | 318 (0.12) | 371 (0.14) | 4.1 (0.5, 7.9)* |
| Multiple cause of death | |||||||
| Hepatocellular carcinoma | 22,482 (8.89) | 22,480 (8.67) | 22,997 (8.68) | 23,062 (8.74) | 23,268 (8.50) | 23,403 (8.52) | –0.8 (–1.4, –0.1)* |
| Intrahepatic cholangiocarcinoma | 7,967 (3.17) | 8,364 (3.26) | 8,589 (3.29) | 9,259 (3.58) | 9,594 (3.58) | 10,450 (3.89) | 4.0 (2.4, 5.7)* |
| Extrahepatic cholangiocarcinoma | 1,043 (0.41) | 1,101 (0.42) | 1,148 (0.43) | 1,180 (0.45) | 1,423 (0.53) | 1,359 (0.50) | 4.8 (1.8, 7.8)* |
| Gallbladder cancer | 2,327 (0.92) | 2,294 (0.89) | 2,439 (0.92) | 2,288 (0.88) | 2,291 (0.85) | 2,372 (0.87) | –1.3 (–3.0, 0.3) |
| Ampullar of Vater cancer | 291 (0.11) | 294 (0.11) | 336 (0.13) | 332 (0.13) | 360 (0.13) | 409 (0.15) | 4.9 (2.2, 7.8)* |
APC, annual percentage change; CI, confidence interval.
*
P<0.05.